2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Molecular Testing, Omics Technologies, Profiling, Treatment Considerations, Combination Therapy, Biological Therapies, Transplantation, Immunotherapy, Monoclonal Antibody Therapy, Adverse Events, Biological Processes, Immune Mechanism, Microbiome, Clinical Practice (Health Services and Quality), Clinical Guidelines, Patient Safety, Practice Models, Quality Improvement, Quality of Care, Diseases, Hemoglobinopathies, Thalassemia, Immunology, GVHD, Immunodeficiency, Infectious Diseases, Viral, Bacterial, Fungal, Lymphoid Malignancies, Lymphoid Leukemias, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, ALL, Research, Fundamental Science, AML, Translational Research, MDS, Clinical Research, Clinical Trials, Patient-Reported Outcomes, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Young Adult, Animal Model
PAPER

4250 Comparison of different GVHD prophylaxis strategies in myelofibrosis patients undergoing allogeneic hematopoietic cell transplantation from matched related donors: A study by the chronic malignancies working party of EBMT

Patrizia Chiusolo, MD, Dirk-Jan Eikema2, Linda Koster3, Francis Ayuk4, Catherine Flynn5, Annoek Broers6, Simona Sica, MD, PhD7, Andrew D Clark, MD, PhD8, Cristina Castilla-Llorente, MD9, Katherine Clesham10, Thomas Cluzeau, MD, PhD11, Lucia Lopez Corral, MD, PhD12, Johan A. Maertens, MD13, Mohamad Mohty, MD, PhD14, Arnon Nagler I, MD15, Thomas Schroeder, MD16, Keith Wilson, MBBS, FRCP, FRCPath17, Nicola Mordini18, Ludek Raida19, Joanna Drozd-Sokolowska, MD, PhD20, Kavita Raj, MD, PhD21, Giorgia Battipaglia22, Tomasz Czerw23, Nicola Polverelli, MD24, Marie Robin, MD25, Juan Carlos Hernandez Boluda, MD, PhD26, Donal McLornan, MD, PhD27
1 Fondandazione Policlinico Universitario A. Gemelli IRCCS-Università Cattolica del Sacro Cuore, Rome, Italy
2 EBMT Leiden Study Unit, Leiden, Netherlands
3 linda.koster@ebmt.org, Leiden, Netherlands
4 University Hospital Eppendorf, hamburg, Germany
5 Hope Directorate - St. James's Hospital, dublin, Ireland
6 Erasmus MC Cancer Institute, rotterdam, Netherlands
7 Fondandazione Policlinico Universitario A. Gemelli IRCCS-Università Cattolica del Sacro Cuore, Rome, Italy
8 Glasgow Royal Infirmary, Glasgow, United Kingdom
9 Gustave Roussy Cancer Campus, Villejuif, France
10 University College London Hospital, london, United Kingdom
11 Hôpital l'Archet I, nice, France
12 Complejo Asistencial Universitario de Salamanca, Salamanca, Spain
13 University Hospital Gasthuisberg, Leuven, Leuven, Belgium
14 Hopital Saint Antoine, paris, France
15 Division of Hematology, Sheba Medical Center,, Tel Hashomer, Israel
16 West German Cancer Centre University Hospital Essen, Essen, Germany
17 South Wales Blood and Marrow Transplant Programme, University Hospital of Wales, Cardiff & Singleton Hospital, Cardiff, United Kingdom
18 Az. Ospedaliera S. Croce e Carlo, Cuneo, Italy
19 Faculty of Medicine and Dentistry of Palacky University in Olomouc, Olomouc, Czech Republic
20 University Clinical Centre, Medical University of Warsaw, Warsaw, Poland
21 University College London Hospitals NHS Trust, London, United Kingdom
22 Department of Clinical Medicine and Surgery, Federico II University of Naples, Italy, Naples, Italy
23 Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice Branch, Poland
24 Fondazione IRCCS Policlinico San Matteo, pavia, Italy
25 Hopital Saint Louis, Paris, France
26 Hospital Clínico Universitario-INCLIVA, Valencia, Spain
27 University College London Hospitals NHS Foundation Trust, London, United Kingdom

Background: Post-transplant cyclophosphamide (PTCy)-based prophylaxis has been extended to matched related donor (MRD) allogeneic hematopoietic cell transplantation (allo-HCT), although limited data are available on its efficacy and safety compared to conventional approaches in myelofibrosis (MF) patients. We evaluated the outcomes of PTCy vs other graft-versus-host disease (GvHD) prophylaxis regimens in MF patients transplanted with MRD, using data from the EBMT registry. 

Methods: A total of 902 MF adult patients undergoing first allo-HCT with a MRD between 2014 and 2022 across 227 participating centers received either PTCY-based (n=58), antithymocyte globulin -based (ATG) (n=526), or conventional prophylaxis (CP) without either PTCY or ATG (n= 318). Patients with history of leukemic transformation were excluded. Primary endpoint of the study was Graft-relapse-free survival (GRFS). 

Results: Overall, 58 patients received PTCY (35 with MMF and CNI), 526 received ATG-based prophylaxis (246 with MMF and 185 with MTX) and 318 received CP (126 with CNI+MMF and 165 with CNI+MTX). Baseline characteristics of the three groups were comparable, except for a higher proportion of patients with HCT-CI>3 in the PTCY group (41% vs 21% and 23%, p<0.001). Median follow-up was shorter in the PTCy group but comparable between the ATG and CP groups, a difference not attributable to higher mortality rates in the PTCY cohort, but to the later introduction of PTCy. Busulfan-based conditioning regimen was used in the majority of pts across all three cohorts. 
GRFS at 2 years was 37% (PTCY), 41% (ATG), and 31% (CP) (p=0.009), being significantly higher for ATG compared to CP (p=0.002), while no statistically significant difference was found comparing PTCy and ATG (p=0.4). Neutrophil engraftment by day +28 was significantly better with ATG and CP compared to PTCy (88% vs 89% vs 77%, p=0.012), while platelet engraftment at day +100 was similar among the three groups (72%, 76%, 75%, p=0.17). With a median follow-up of 36.9 months, 2-ys OS rates were 67% (PTCy), 71% (ATG), 63% (CP) (p=0.3).  
The 2-yr PFS was 56% (PTCY), 56% (ATG), and 58% (CP) (p=0.7). The 2-yr cumulative incidence of relapse was 29% with PTCY, 22% with ATG and 15% with CP, with no significant difference between PTCy and ATG (p=0.4), while CIR was significantly higher with both PTCy and ATG compared to CP (p=0.038 and p=0.006, respectively). There was no significant difference in 2-yr non-relapse mortality (NRM) rates across the 3 groups: 15% in PTCy, 22% in ATG and 27% in CP. CI of Grade II-IV aGvHD was 14% for PTCY, 18% for ATG, 29% for CP, with significant differences between PTCy and CP (p=0.011) and between ATG and CP (p<0.001). CI of extensive cGvHD at 2-yr was 23% for PTCy, 22% for ATG, 33% for CP, with a statistically significant difference between ATG and CP (p<0.001). In multivariable analysis for GRFS, the only variables associated with a worse outcome were a melphalan-based conditioning regimen and JAK2 mutation. For OS and PFS, beyond JAK2 mutation, Karnofsky status <80%, older age, and high DIPSS score were also significantly associated with a worse outcome.

Conclusions: Despite the shorter follow-up in PTCY cohort, which can underestimate late complications, these results suggest that in the setting of MRD-HCT for MF, PTCy appear to be a feasible GvHD prophylaxis platform in MRD allo-HCT for MF. However its use is associated with a significant delay in neutrophil engraftment compared to other GVHD prophylaxis strategies. The addition of PTCy or ATG to CP results in decreased incidence of grades 2-4 aGvHD and cGvHD, but higher relapse rate. While no differences in OS are observed across the three groups, the 2-yr GRFS with PTCy or ATG is slightly higher than with CP. Although univariable analysis demonstrated improved GRFS with ATG versus CP, no prophylaxis platform remained independently associated with GRFS in multivariable analysis.

 

Patrizia Chiusolo, MD: Abbvie, Astellas and Otsuka - Honoraria